Will You Need a GLP-1 Forever? What Happens When You Stop

Patients ask me a version of this almost every week: if I start a GLP-1 medication like tirzepatide, am I on it for life? It's the right question, and the honest answer is uncomfortable. For most people, stopping means regaining, often fast, unless you use the time on the medication to change something deeper. Here's what the evidence shows, and how to think about it.

What these medications do, and don't, fix

GLP-1 medications work, and they work well. In SURMOUNT-1, Jastreboff and colleagues found that tirzepatide produced average weight loss of about 15 to 21 percent of body weight over 72 weeks [1]. The drug quiets appetite, slows how fast your stomach empties, and makes eating less feel effortless. What it doesn't do is rewrite the habits, the metabolism, or the food environment that built the weight in the first place. It manages the symptom beautifully while the underlying drivers wait in the background.

What happens when you stop

Here's where the question gets answered directly. When the medication stops, appetite comes back, and so does the weight. In SURMOUNT-4, Aronne and colleagues took people who'd already lost weight on tirzepatide and switched half of them to placebo; that group regained much of what they'd lost, while the people who kept treatment held steady [2]. The same pattern shows up across the drug class. In the STEP-1 trial extension, Wilding and colleagues followed people for a year after stopping semaglutide and found they regained about two-thirds of their lost weight, with much of the metabolic improvement reversing alongside it [3].

Read together, these trials send a blunt message. The weight loss lasts as long as the medication does, unless something else changes.

Why the regain happens

The regain isn't a failure of willpower; it's biology. Your body defends a higher weight, partly through hunger hormones that rebound when the medication is withdrawn. The drug had been holding that drive down. Take it away, and the drive comes back, often stronger. Add a life that hasn't changed, the same food, the same routines, and the result is predictable.

The way out: use the window

This reframes how to use a GLP-1, and it's genuinely hopeful. The months on the medication aren't the treatment; they're the window. While appetite is quiet and the weight is coming off, you can do the work that normally feels impossible when you're ravenous: build a protein-forward way of eating, learn to fast comfortably, add the resistance training that protects muscle, and improve the metabolic markers underneath. People who use that window to change those things have something to stand on when the medication tapers, while those who don't end up regaining what they lost.

That's also why we use lower micro-doses and pair the medication with lab work, coaching, and follow-up instead of handing over a prescription and stepping back. The goal isn't to keep you on a drug forever. It's to make the drug temporary by using its window well.

Honest caveats

Two things to keep straight. For some people, obesity behaves like a chronic disease, and long-term medication is a legitimate, evidence-based choice, the same way someone stays on blood pressure medication. Staying on a GLP-1 isn't a failure, and nobody should start or stop these medications on their own. The point isn't that the drug is bad. It's that the drug alone, without the lifestyle change underneath, rarely produces a lasting result.

Start your visit

References

1. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022. PMID: 35658024
2. Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024. PMID: 38078870
3. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022. PMID: 35441470
4. Further reading: analysis of weight regain after GLP-1 discontinuation. BMJ. 2025. bmj.com